Clinical trials: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), open to volunteers

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

• Enrolling by invitation
• Age: 18 years and older
• Phase 3
• Injection or infusion

The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.

Trial name

NCT05667493

Testing

Eplontersen

Where

134 sites in United States, Argentina and 18 more

Volunteers

1,400 people

Sponsor

Ionis Pharmaceuticals, Inc.